Andrew Reardon Ligand Pharmaceuticals Inc (LGND) insider trading activity

Andrew Reardon is CLO & Secretary of LIGAND PHARMACEUTICALS INC. Currently has a direct ownership of 34,783 shares of LGND, which is worth approximately $3.74 Million. The most recent transaction as insider was on Mar 04, 2025, when has been sold 6,415 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 34.8K

54.36% 3M change

56.64% 12M change

Total Value Held $3.74 Million

Andrew Reardon Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 04 2025	BUY Grant, award, or other acquisition	-	6,415 Added 15.57%	34,783 Common Stock
Feb 15 2025	SELL Payment of exercise price or tax liability	$238,800 $120.0 p/Share	1,990 Reduced 6.56%	28,368 Common Stock
Feb 14 2025	SELL Payment of exercise price or tax liability	$543,960 $120.0 p/Share	4,533 Reduced 12.99%	30,358 Common Stock
Feb 14 2025	BUY Grant, award, or other acquisition	-	12,357 Added 27.79%	32,116 Common Stock
Sep 23 2024	SELL Open market or private sale	$199,200 $99.6 p/Share	2,000 Reduced 8.15%	22,534 Common Stock
Sep 23 2024	BUY Exercise of conversion of derivative security	$104,540 $52.27 p/Share	2,000 Added 7.54%	24,534 Common Stock
Aug 28 2024	SELL Open market or private sale	$159,585 $106.39 p/Share	1,500 Reduced 6.24%	22,534 Common Stock
Aug 28 2024	BUY Exercise of conversion of derivative security	$78,405 $52.27 p/Share	1,500 Added 5.87%	24,034 Common Stock
Jun 28 2024	BUY Other acquisition or disposition	$19,973 $60.71 p/Share	329 Added 1.44%	22,534 Common Stock
May 09 2024	SELL Open market or private sale	$830,400 $83.04 p/Share	10,000 Reduced 31.05%	22,205 Common Stock
May 09 2024	BUY Exercise of conversion of derivative security	$522,700 $52.27 p/Share	10,000 Added 23.69%	32,205 Common Stock
Feb 27 2024	BUY Grant, award, or other acquisition	-	7,208 Added 24.51%	22,205 Common Stock
Feb 15 2024	SELL Payment of exercise price or tax liability	$44,267 $74.65 p/Share	593 Reduced 3.8%	14,997 Common Stock
Dec 29 2023	BUY Other acquisition or disposition	$10,867 $60.71 p/Share	179 Added 1.14%	15,590 Common Stock
Aug 10 2023	SELL Payment of exercise price or tax liability	$61,650 $68.73 p/Share	897 Reduced 5.5%	15,411 Common Stock
Mar 24 2023	SELL Open market or private sale	$20,976 $69.92 p/Share	300 Reduced 1.81%	16,308 Common Stock
Feb 23 2023	BUY Grant, award, or other acquisition	-	5,668 Added 25.44%	16,608 Common Stock
Nov 30 2022	SELL Payment of exercise price or tax liability	$78,221 $72.9 p/Share	1,073 Reduced 8.93%	10,940 Common Stock

Andrew Reardon

CLO & Secretary

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LGND shares.

Notify only if

Value

Insider Trading

Get notified when an Ligand Pharmaceuticals Inc insider buys or sells LGND shares.

Notify only if

Operation

Value

Type

News

Receive news related to LIGAND PHARMACEUTICALS INC

Track Activities on LGND

Account